On-Demand Webinar:

Nose-to-Brain Drug Delivery and Device Selection

Share this webinar

LinkedIn

Description

Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes—focusing especially on the critical role of device selection. Attendees will learn how spray pattern, droplet size, and dosing precision can significantly affect drug deposition within the nasal cavity and influence therapeutic effectiveness, particularly in targeting the olfactory region.

The discussion will delve into the importance of harmonising formulation properties with device capabilities to improve bioavailability, stability, and patient adherence. Whether dealing with liquid or dry powder formulations, understanding the nuances of device compatibility is key to overcoming physiological barriers like the blood-brain barrier. We’ll present strategies that integrate formulation science with engineering insights to create viable, efficient nasal dosage forms. Practical device testing methodologies will be examined highlighting how these tools generate data to support robust regulatory submissions and product development decisions.

You’ll gain a comprehensive understanding of the benefits and challenges of Nose-to-Brain (N2B) delivery, including key delivery targets and transport mechanisms. The session will provide a clear view of how smart device selection, paired with tailored formulation development approaches, can unlock more consistent and effective CNS delivery outcomes. Join us to discover how to accelerate your nasal drug development pathway from pre-clinical to market.

Our Speakers

Richard Johnson

Chief Scientific Officer & Founder, Upperton Pharma Solutions

Lara Penn

Lara Penn

Senior Development Scientist II, Upperton Pharma Solutions

Dr Richard Johnson is the Founding Director and Chief Scientific Officer at Upperton Pharma Solutions, a UK-based Contract, Development and Manufacturing Organisation (CDMO) and graduated from Warwick University with a PhD Biochemistry. In 1994 he was part of a management buy-out team that founded Andaris Ltd, a research and development company exploiting the use of spray drying technology in the fields of diagnostic imaging and drug delivery. In 1999, Dr Johnson founded Upperton and has overseen significant growth and expansion over the past 25 years, specialising in spray drying and nasal drug development.
Lara Penn is a Senior Development Scientist II at Upperton Pharma Solutions in Nottingham. She holds a BSc in Pharmaceutical Chemistry from the University of Leicester. With over five years of experience, Lara has progressed from Quality Control Scientist to senior roles in formulation and project development. She specialises in analytical testing, method validation, and formulation development of oral solid dosage forms. Lara applies a science-led approach to support efficient development and manufacturing under GMP. She is skilled in HPLC, UV-Vis, FTIR, dissolution testing, and preparing technical documentation and SOPs.

What You Will Learn

  • Understanding of barriers to successful brain/CNS delivery: Blood-brain barrier.
  • The benefits and challenges of Nose to Brain (N2B) Delivery.
  • Delivery Targets and Transport Mechanisms for Nose to Brain (N2B) Delivery.
  • Developing nasal dosage forms.
  • Liquid v Dry Powder and Formulation Considerations.
  • Device Considerations for Nose to Brain (N2B) delivery.
  • Practical insights into device testing methods including AINI

Addressed Challenges

  • Learn how formulation and device alignment can help to overcome and improve drug deposition in the olfactory region.

Watch now

Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes, focusing especially on the critical role of device selection.

Key topics covered

  • Understanding of barriers to successful brain/CNS delivery: Blood-brain barrier.
  • The benefits and challenges of Nose to Brain (N2B) Delivery.
  • Delivery Targets and Transport Mechanisms for Nose to Brain (N2B) Delivery.
  • Developing nasal dosage forms.
  • Liquid v Dry Powder and Formulation Considerations.
  • Device Considerations for Nose to Brain (N2B) delivery.
  • Practical insights into device testing methods including AINI

Download Our Fact Sheet: The New Rules of CDMO Partnerships

What Biotechs Should Be Looking For Next

Let's Talk.

Book a discovery call.

Speak with our team of experts and set up a discovery call to discuss your project in more detail.